The modulatory effects of bradykinin B1 and B2 receptor antagonists upon viscero-visceral hyper-reflexia in a rat model of visceral hyperalgesia.
This study assessed the relative involvement of the two bradykinin (Bk) receptors (B1 and B2) in the viscero-visceral hyper-reflexia (VVH) and plasma extravasation observed in an animal model of cystitis. The effects of the competitive receptor antagonists des-Arg9[Leu8]-Bk (B1) and HOE 140 (B2) were tested both in prophylactic (pre-inflammation administration) and therapeutic (post-inflammation administration) scenarios. Compared with control animals, des-Arg9[Leu8]-Bk had no effect on the hyper-reflexic response of the bladder to inflammation unless it was administered 5 h after inflammation. However, HOE 140 was able to attenuate the inflammation-induced viscero-visceral hyper-reflexia (VVH) at doses of 1 mg/kg, 2 mg/kg and 7.5 mg/kg. This effect was apparent whether the drug was administered before, or after inflammation. In contrast, neither compound was effective in attenuating the intravesical plasma extravasation induced by turpentine. The data therefore suggest that the VVH and tissue inflammation responses are mediated via different mechanisms. In addition, the turpentine-induced VVH appears to be mediated, at least partially, by the B2 receptor in the early phase, with the B1 receptor only becoming important later.
Jaggar
S I
SI
Department of Anaesthetics, Imperial College School of Medicine, St. Mary's Hospital, London, UK.
Habib
S
S
Rice
A S
AS
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001920:Bradykinin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D004396:Coloring Agents / Q000493:pharmacokinetics; D003556:Cystitis / Q000503:physiopathology*; D005070:Evans Blue / Q000493:pharmacokinetics; D005260:Female; D006930:Hyperalgesia / Q000503:physiopathology*; D051381:Rats; D017208:Rats, Wistar; D012021:Reflex, Abnormal / Q000187:drug effects*; D001743:Urinary Bladder / Q000378:metabolism; D014781:Viscera / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D065168:Bradykinin Receptor Antagonists; D004396:Coloring Agents; D005070:Evans Blue; C051090:bradykinin, Leu(8)-des-Arg(9)-; C065679:icatibant; D001920:Bradykinin